Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for the year 2024. For the period, the company expects net revenue to be between $360 million and $380 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.5 USD | -3.44% | -2.09% | +12.09% |
23/04 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
23/04 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.09% | 1.43B | |
+3.92% | 108B | |
+11.29% | 104B | |
+1.28% | 22.33B | |
-12.98% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.76% | 17.64B | |
+3.67% | 14.05B | |
+35.92% | 12.51B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024